Limbix is the creator of SparkRx, a PDTx that makes use of the ideas of cognitive behavioral remedy to deal with despair in teenagers and younger adults ages 13 to 22.
The self-guided CBT-based therapy was released in October 2021 as a part of the FDA’s relaxed regulatory requirements for digital well being gadgets treating psychiatric problems through the pandemic.
SparkRx might be added to Huge Well being’s portfolio, which incorporates Daylight therapeutic for nervousness and Sleepio for insomnia.
“Limbix and Huge Well being share vital alignment in our cultures and in our give attention to delivering first-line digital therapeutics for a spread of psychological well being circumstances,” Ben Lewis, cofounder and CEO of Limbix, mentioned in an announcement. “Because the trade chief, Huge Well being is a pure residence for SparkRx, our upcoming product pipeline and our workforce to speed up giving younger folks instruments they’ll use themselves to meaningfully profit from clinically-proven digital despair therapies,” he added.
THE LARGER TREND
In 2021, Limbix scooped up $15 million in Series A2 funding, bringing its complete increase to $31 million.
In 2020, the corporate scored $9 million in Series A funding, roughly 4 months after the Palo Alto-based startup was one among 27 digital well being firms chosen in MassChallenge HealthTech’s 2020 accelerator class.
In 2020, CVS Health introduced it was adding a handful of digital health apps to its Level Resolution Administration service, together with Huge Well being’s Daylight. The retail big mentioned Level Resolution goals to assist CVS Caremark pharmacy advantages administration shoppers enroll in third-party well being apps.